Related Experiment Video
Updated: Jun 10, 2026
11:34
Building Up a High-throughput Screening Platform to Assess the Heterogeneity of HER2 Gene Amplification in Breast Cancers
Published on: December 5, 2017
HER2 fragmentation and breast cancer stratification
Joaquín Arribas1, Josep Lluís Parra-Palau, Kim Pedersen
1Vall d'Hebron Institute of Oncology, Barcelona, Spain. jarribas@vhio.net
Summary
Human Epidermal growth factor Receptor 2 (HER2) overexpression in breast cancer indicates a poor prognosis. A specific HER2 fragment, p95HER2, is a promising biomarker for identifying patients with particularly aggressive disease.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- HER2 is a tyrosine kinase receptor frequently overexpressed in breast cancers.
- HER2 overexpression is associated with aggressive tumor behavior and poor patient prognosis.
- A subset of HER2-positive tumors express truncated HER2 variants, known as p95HER2.
Purpose of the Study:
- To investigate the clinical significance of p95HER2 expression in breast cancer.
- To evaluate p95HER2 as a potential biomarker for identifying patients with a poor prognosis.
Main Methods:
- Analysis of HER2 and p95HER2 expression in tumor samples.
- Correlation of expression levels with clinical outcomes and patient prognosis.
Main Results:
- p95HER2 expression is found in a subset of HER2-positive breast cancers.
- The presence of p95HER2 correlates with a particularly poor prognosis in these patients.
Conclusions:
- p95HER2 represents a significant emerging biomarker in HER2-positive breast cancer.
- Identification of p95HER2 may aid in stratifying patients for targeted therapies and predicting outcomes.
